Cencora delivered 6% and 20% revenue and adjusted EPS growth, respectively, during the fourth fiscal quarter. Both figures landed ahead of FactSet consensus. Fiscal 2027 guidance includes 4% and 9% revenue and EPS growth, respectively, at midpoint. Shares are up 3% intraday Nov. 4.
Cencora distributes pharmaceutical products to nearly one-third of the industry, leading to substantial negotiation leverage with drug manufacturers.
Reimbursement pressures on pharmacy and provider customers have led to an emphasis on cost containment, pressuring Cencora's profitability.
Metric | COR | CAH | MCK |
|---|---|---|---|
Price/Earnings (Normalized) | 20.94 | 23.13 | 26.04 |
Price/Book Value | 18.08 | — | — |
Price/Sales | 0.20 | 0.25 | 0.31 |
Price/Cash Flow | 16.49 | 17.86 | 19.24 |
Metric | COR | CAH | MCK |
|---|---|---|---|
Quick Ratio | 0.48 | 0.43 | 0.50 |
Current Ratio | 0.93 | 0.88 | 0.90 |
Interest Coverage | 7.89 | 7.64 | 22.07 |
Metric | COR | CAH | MCK |
|---|---|---|---|
Return on Assets (Normalized) | — | 4.78% | 5.95% |
Return on Equity (Normalized) | — | — | — |
Return on Invested Capital (Normalized) | — | 48.63% | 56.87% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| McKesson Corp MCK | LOCK|^!#LF>J | LOCK|B<lc | $125B | |||
| Cardinal Health Inc CAH | LOCK|H!Ws&r | LOCK|t>HZK | $64B | |||
| Sigma Healthcare Ltd SIGGF | — | LOCK|q@c@ | $23B | |||
| Henry Schein Inc HSIC | LOCK|lKwm#H | LOCK|<lCL! | $10B | |||
| Shanghai Pharmaceuticals Holding Co Ltd ADR SHPMY | — | LOCK|X# | $8B | |||
| Sinopharm Group Co Ltd SHTDF | — | LOCK|Vl | $7B | |||
| Sinopharm Group Co Ltd ADR SHTDY | — | LOCK|hj | $7B | |||
| Galenica Ltd GALNF | — | LOCK|z@d | $5B | |||
| Medipal Holdings Corp MEPDF | — | LOCK|z# | $4B |
United States